IQVIA (NYSE:IQV) Price Target Lowered to $210.00 at Robert W. Baird

IQVIA (NYSE:IQV) had its target price dropped by stock analysts at Robert W. Baird from $212.00 to $210.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s price target would suggest a potential upside of 2.26% from the company’s current price.

A number of other research firms also recently weighed in on IQV. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Stephens started coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective on the stock. BTIG Research lowered their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a report on Friday, November 1st. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Finally, Morgan Stanley lowered their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $255.71.

IQVIA Trading Down 0.2 %

NYSE IQV opened at $205.37 on Tuesday. The firm has a market capitalization of $37.27 billion, a PE ratio of 26.95, a P/E/G ratio of 2.01 and a beta of 1.48. The stock’s 50 day moving average is $199.53 and its 200 day moving average is $221.30. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IQV. Simplify Asset Management Inc. raised its stake in IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after buying an additional 3,894 shares during the last quarter. Nordea Investment Management AB increased its position in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Versor Investments LP bought a new position in IQVIA in the third quarter valued at about $1,328,000. JPMorgan Chase & Co. boosted its position in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Finally, CIBC Asset Management Inc grew its stake in shares of IQVIA by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock valued at $62,501,000 after purchasing an additional 8,490 shares during the period. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.